Officials give final OK to limit state health plan spending on Ozempic, Jardiance

State officials gave final approval Monday to regulations that cap how much state and local governments are willing to pay for two high-cost drugs by setting “upper payment limits” on treatments for Type 2 diabetes and other conditions.

The Prescription Drug Affordability Board action set payment limits on two prescription drugs covered by state healthcare plans: Jardiance, a brand name for the drug empagliflozin, and Ozempic, a name brand for semaglutide.

The vote finalizes language that now goes to the state register for final evaluation. If no problems arise there, the new regulations would go into effect on Jan. 1, 2027, marking the first time the board has limited spending on high cost drugs since it was created in 2019…

Story continues

TRENDING NOW

LATEST LOCAL NEWS